SPOTLIGHT: Sysmex, Matritech end pact

Sysmex and Matritech have dissolved a 2002 agreement under which Sysmex was granted a license for the use of Matritech's NMP 179 cervical cancer technology. Matritech, which is focused on point-of-care diagnostic tests, was recently acquired by Inverness Medical Innovations. Release

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.